Akhtar Waqas, Olusanya Olusegun, Baladia Marta Montero, Young Harriet, Shah Sachin
Department of Intensive Care, St Bartholomew's Hospital, London, EC1A 7BE UK.
Indian J Thorac Cardiovasc Surg. 2021 Jan;37(1):53-60. doi: 10.1007/s12055-020-01084-y. Epub 2020 Nov 24.
In this paper, we describe our experience and early outcomes with critically unwell severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients who required extracorporeal membrane oxygenation (ECMO). We present our standard practices around ECMO decision-making, retrieval, cannulation, ventilation, anticoagulation, tracheostomy, imaging and steroids.
A retrospective cohort study using data from the hospital notes on all SARS-CoV-2 patients who required extracorporeal support at St Bartholomew's Hospital between 1 March 2020 and 31 July 2020. In total, this included 18 patients over this time period.
In total, 18 patients were managed with extracorporeal support and of these 14 survived (78%) with 4 deaths (22%). The mean duration from hospital admission to intubation was 4.1 ± 3.4 days, mean time from intubation to ECMO 2.3 ± 2 days and mean run on ECMO 17.7 ± 9.4 days. Survivor mean days from intubation to extubation was 20.6 ± 9.9 days and survivor mean days from intubation to tracheostomy decannulation 46.6 ± 15.3 days. Time from hospital admission to discharge in survivors was a mean of 57.2 ± 25.8 days. Of the patients requiring extracorporeal support, the initial mode was veno-venous (VV) in 15 (83%), veno-arterial (VA) in 2 (11%) and veno-venous-arterial (VVA) in 1 (6%). On VV extracorporeal support, 2 (11%) required additional VVA. Renal replacement therapy was required in 10 (56%) of the patients. Anticoagulation target anti-Xa of 0.2-0.4 was set, with 10 (56%) patients having a deep vein thrombosis or pulmonary embolism detected and 2 (11%) patients suffering an intracranial haemorrhage. Tracheostomy was performed in 9 (50%) of the patients and high-dose methylprednisolone was given to 7 (39%) of the patients.
In our cohort of patients with severe SARS-CoV-2 respiratory failure, a long period of invasive ventilation and extracorporeal support was required but achieving good outcomes despite this. There was a significant burden of thromboembolic disease and renal injury. A significant proportion of patients required tracheostomy and steroids to facilitate weaning.
在本文中,我们描述了对需要体外膜肺氧合(ECMO)的危重症严重急性呼吸综合征冠状病毒2(SARS-CoV-2)患者的治疗经验和早期治疗结果。我们介绍了围绕ECMO决策、转运、插管、通气、抗凝、气管切开、影像学检查和使用类固醇的标准做法。
一项回顾性队列研究,使用2020年3月1日至2020年7月31日期间圣巴塞洛缪医院所有需要体外支持的SARS-CoV-2患者的医院病历数据。在此期间,总共包括18例患者。
总共18例患者接受了体外支持治疗,其中14例存活(78%),4例死亡(22%)。从入院到插管的平均时间为4.1±3.4天,从插管到ECMO的平均时间为2.3±2天,ECMO的平均使用时间为17.7±9.4天。存活者从插管到拔管的平均天数为20.6±9.9天,存活者从插管到气管切开拔管的平均天数为46.6±15.3天。存活者从入院到出院的平均时间为57.2±25.8天。在需要体外支持的患者中,初始模式为静脉-静脉(VV)的有15例(83%),静脉-动脉(VA)的有2例(11%),静脉-静脉-动脉(VVA)的有1例(6%)。在VV体外支持下,2例(11%)需要额外的VVA。10例(56%)患者需要肾脏替代治疗。抗凝目标抗Xa设定为0.2-0.4,10例(56%)患者检测到深静脉血栓形成或肺栓塞,2例(11%)患者发生颅内出血。9例(50%)患者进行了气管切开,7例(39%)患者给予了大剂量甲泼尼龙。
在我们的重症SARS-CoV-2呼吸衰竭患者队列中,需要长时间的有创通气和体外支持,但尽管如此仍取得了良好的治疗效果。血栓栓塞性疾病和肾损伤负担较重。相当一部分患者需要气管切开和使用类固醇以促进脱机。